title: Arterial enhancement of hepatocellular carcinoma before radiofrequency ablation as a predictor of postablation local tumor progression.
abstract: OBJECTIVE
  The purpose of our study was to elucidate whether the degree of arterial enhancement on CT is a significant risk factor for local tumor progression after percutaneous radiofrequency ablation of hepatocellular carcinomas (HCCs) larger than 2 cm.
  
  
  METHODS
  Percutaneous radiofrequency ablation procedures to treat 203 previously untreated HCCs larger than 2 cm in 190 patients were analyzed retrospectively. We assessed the technique effectiveness rate 1 month after the procedure and the cumulative local tumor progression rate. The tumors were classified into one of the following groups for qualitative analysis: group with evident contrast enhancement or group showing subtle or no contrast enhancement. We performed quantitative analysis of increments in the attenuation (in Hounsfield units [HU]) from unenhanced to arterial phase CT of the 78 HCCs for which unenhanced CT was available. To determine any significant risk factor, various factors, including the degree of arterial enhancement, were tested by multivariate analysis.
  
  
  RESULTS
  The technique effectiveness rate was 99.0% (201/203). Local tumor progression was detected in 23.9% (48/201), and the cumulative rates of local tumor progression at 1, 2, and 3 years were 12.9%, 23.1%, and 27.6%, respectively. The two qualitative groups were significantly different in their cumulative local tumor progression rates (p = 0.009). Multivariate analysis revealed that the degree of arterial enhancement was a sole independent significant risk factor for local tumor progression (p = 0.026).
  
  
  CONCLUSIONS
  A high degree of arterial enhancement on CT after percutaneous radiofrequency ablation of HCCs larger than 2 cm is a significant risk factor for local tumor progression.
authors.affiliation: Department of Radiology, Center for Imaging Science, Samsung Medical Center, Sunkyunkwan University School of Medicine, [corrected] 50, Ilwon-dong, Gangnam-gu, Seoul 135-710, Korea.
authors.forename: Yulri
authors.initials: Y
authors.lastname: Park
authors.forename: Young-Sun
authors.initials: YS
authors.lastname: Kim
authors.forename: Hyunchul
authors.initials: H
authors.lastname: Rhim
authors.forename: Hyo Keun
authors.initials: HK
authors.lastname: Lim
authors.forename: Dongil
authors.initials: D
authors.lastname: Choi
authors.forename: Won Jae
authors.initials: WJ
authors.lastname: Lee
mesh_terms: D000368:Aged; D001158:Arteries; D006528:Carcinoma, Hepatocellular / Q000098:blood supply / Q000000981:diagnostic imaging* / Q000473:pathology / Q000601:surgery*; D017115:Catheter Ablation; D003287:Contrast Media / Q000008:administration & dosage; D018450:Disease Progression; D005260:Female; D006801:Humans; D007472:Iohexol / Q000008:administration & dosage / Q000031:analogs & derivatives; D008113:Liver Neoplasms / Q000098:blood supply / Q000000981:diagnostic imaging* / Q000473:pathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011857:Radiographic Image Interpretation, Computer-Assisted; D012189:Retrospective Studies; D012307:Risk Factors; D014057:Tomography, X-Ray Computed / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D003287:Contrast Media; D007472:Iohexol; C038192:iopromide